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Blindness due to corneal diseases is a common pathology affecting up to 23 million
individuals worldwide. The tissue‐engineered anterior human cornea, which is cur-
rently being tested in a Phase I/II clinical trial to treat severe corneal trophic ulcers
with preliminary good feasibility and safety results. This bioartificial cornea is based
on a nanostructured fibrin–agarose biomaterial containing human allogeneic stromal
keratocytes and cornea epithelial cells, mimicking the human native anterior cornea- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Grant/Award Number: EC10‐285in terms of optical, mechanical, and biological behavior. This product is manufactured
as a clinical‐grade tissue engineering product, fulfilling European requirements and
regulations. The clinical translation process included several phases: an initial in vitro
and in vivo preclinical research plan, including preclinical advice from the Spanish
Medicines Agency followed by additional preclinical development, the adaptation of
the biofabrication protocols to a good manufacturing practice manufacturing process,
including all quality controls required, and the design of an advanced therapy clinical
trial. The experimental development and successful translation of advanced therapy
medicinal products for clinical application has to overcome many obstacles, especially
when undertaken by academia or SMEs. We expect that our experience and research
strategy may help future researchers to efficiently transfer their preclinical results into
the clinical settings.
KEYWORDS
advanced therapy medicinal products (ATMPs), clinical translation, cornea, preclinical research,
regulatory issues, tissue‐engineered anterior human cornea (TEAHC), tissue engineering1 | INTRODUCTION
Tissue engineering and regenerative medicine (TERM) have achieved
important advancements in the last decades, bringing new therapeutic
possibilities by improving restoration of tissues and biological func-
tions using therapeutic cells and tissues (Harrison, St‐Pierre, & Ste-
vens, 2014). Multiple models of advanced therapy medicinal
products (ATMPs) have been generated in the laboratory, and tissue
engineering and regenerative medicine technology has been applied
to various tissues and organs, offering a paradigm shift from conven-
tional donor organ or tissue transplantation. However, the number of
patients treated so far suggests an important imbalance between sci-
entific innovation and clinical translation (Martin, Ireland, Baldomero,
& Passweg, 2015). The development of new ATMPs is not straightfor-
ward, as many challenges have been observed during the past years:
for example, traditional approaches may not be applicable, and the
characterization of the product itself may pose some problems (Celis
et al., 2015; Cuende & Izeta, 2010).
Cornea transplantation—keratoplasty—is the most frequent trans-
plant worldwide (Whitcher, Srinivasan, & Upadhyay, 2001). However,
despite overall good success rates, results are suboptimal in high‐risk
patients with inflammation and severe pathologies (e.g., chemical
burns, autoimmune diseases, previously rejected grafts, or peripheral
thinning), and transplants long‐term survival is approximately 60% at
10 years (Coster & Williams, 2005). Additionally, a severe shortage
of good quality donor corneas is seen in many countries with only
one cornea available for 70 needed (Gain et al., 2016; Wong, Kam,
Chen, & Young, 2017). Hence, there is a need to develop alternative
solutions when facing this disease, such as corneal bioengineering.
For over a decade now, our group has been developing an
organotypic substitute of the anterior human cornea. The human cor-
nea is a transparent, 0.5‐mm thick, nonvascular organ whose mainfunctions are to (a) protect the inner eye tissues against external
agents and (b) to provide an essential refractive power to allow focus-
ing of light into the eye. It is composed of five layers: the epithelium,
Bowman's layer, the stroma, the Descemet membrane, and the endo-
thelium (Meek & Knupp, 2015). Our allogeneic tissue‐engineered
anterior human cornea (TEAHC) is a two‐layer construct composed
of stromal keratocytes immersed in a fibrin–agarose scaffold and cor-
neal epithelial cells seeded onto the surface of the scaffold (Miguel
Alaminos et al., 2006). To improve biomechanical properties, the
TEAHC is subjected to a plastic compression (nanostructuration),
based on methods previously described, without affecting cell viability
(De La Cruz Cardona et al., 2011; Hadjipanayi et al., 2011; Ionescu et
al., 2011; Scionti et al., 2014).
Traditional corneal transplantation is the only widely accepted
treatment to restore sight in patients suffering from severe corneal
blindness; however, shortage of good quality donor corneas is prev-
alent (Gain et al., 2016). Furthermore, in high‐risk clinical cases
(chemical burns, inflammatory/2autoimmune diseases, previously
rejected grafts, peripheral thinning, etc.), donor corneal transplanta-
tion is not an option due to complications and high failure rates
(Yu et al., 2014). Tissue‐engineered corneas like TEAHC present
numerous advantages over eye bank native corneas: controlled
manufacturing avoiding the need for expensive individual screening
tests, high volume production with readily available bioengineered
corneal substitutes, or specific tailoring of the corneal substitute's
biomechanical, optical, or functional properties.
In this report, we provide details of our successful experience in
the development and clinical translation of a tissue engineering prod-
uct for the treatment of eye surface disorders. From its preclinical
development planning, and complementary research as advised by
the Spanish Agency of Medicines and Medical Devices (AEMPS), to
the adaption of production protocols to obtain a clinical‐grade
2144 RICO‐SÁNCHEZ ET AL.product, and eventually the design of a small‐scale Phase I/II clinical
trial that is currently ongoing (NCT01765244, registered January 9,
2013; EudraCT 2010‐024290‐40; Miguel González‐Andrades et al.,
2017). Although not the first (Pellegrini et al., 2018), this is a
significant development in the field of tissue engineering providing
the roadmap for other ATMPs developers in the area to navigate over
the complex scientific and regulatory hurdles on the way to human
clinical trials.2 | METHODS
2.1 | Generation of a bioengineered anterior lamellar
human cornea (TEAHC)
A bioengineered substitute of the anterior human cornea was gener-
ated at the Tissue Engineering Group of the University of Granada
using fibrin–agarose nanostructured sheets as previously described
(Gonzalez‐Andrades et al., 2009). Prior local IRB approval of the pro-
duction validation protocol was obtained, as it involved human cadav-
eric samples. Briefly, small biopsies of the human scleral limbus were
obtained according to the protocols established by the Spanish
National Organization for Human Transplantation. For the use of
human sclero‐corneal limbi, which are normally by‐products of the cor-
neal transplant surgery or donor corneas with suboptimal quality for
keratoplasty, a written approval consent form was obtained from the
legal representatives. Limbal explant methods were used to generate
primary cell cultures of epithelial cells, whereas the stromal
keratocytes were isolated from fragments of corneal stroma attached
to the sclero‐corneal limbus. Both cell types are allogeneic but not
necessarily from the same donor. Epithelial and stromal cell culturesFIGURE 1 Primary cell cultures and tissue‐engineered anterior human co
of the TEAHC. (b) Phase‐contrast microscopic images of cultured stromal k
epithelial cells. (d) Macroscopic image of the artificial cornea after being su
cornea stained with hematoxylin and eosin. (f) TEAHC implanted in the co
[Colour figure can be viewed at wileyonlinelibrary.com]were then isolated and expanded in specific culture media using a
sequential culture technique. Keratocytes were immersed within a
hydrogel consisting of human plasma obtained from blood donors
and 0.1% Type VII agarose. Fibrin was obtained from frozen plasma
of human blood donors (provided and certified by the “Centro deTrans-
fusión, Tejidos y Células,” Granada, under current national regulations;
Real Decreto‐ley 9/2014). Tranexamic acid was used to prevent fibri-
nolysis, and calcium chloride was added to induce jellification of the
biomaterial. Cornea epithelial cells were then seeded onto the surface
of the constructed stromal model. When epithelial cells reached con-
fluence, stratification and differentiation of the epithelial cell layer is
promoted using air–liquid culture techniques on cell culture inserts
with 0.4 μm porous membranes (Transwell, Corning‐Costar, Corning,
NY, USA). Once generated, the TEAHC was subjected to plastic com-
pression (nanostructuration, patent P200930625) in order to improve
the biomechanical properties of the product (Figure 1a). This protocol
was then adapted to fulfill all regulatory requirements for ATMP
manufacturing according to good manufacturing practice (GMP) stan-
dards (clinical‐grade therapeutic product), as described below.
2.2 | In vitro product characterization
The first step of the characterization process is identifying the features
of both isolated cell types in culture as well as in the final product
itself. For histological analysis, TEAHC‐bioengineered corneas were
fixed in 4% formaldehyde, dehydrated in an ethanol series, and
embedded in paraffin. Cross sections were cut, 4 μm thick, stained
with hematoxylin and eosin, and examined with a light microscope.
On the other hand, phase‐contrast microscopy was used as a method
for morphological evaluation of primary cultured cells. Under these
conditions, stromal keratocytes display an elongated spindle‐like shapernea (TEAHC) generated by tissue engineering. (a) Schematic structure
eratocytes. (c) Phase‐contrast microscopic images of cultured corneal
bjected to nanostructuration. (e) Histological analysis of the artificial
rneal lesion using interrupted 10–0 nylon sutures. Scale bar: 100 μm
TABLE 1 Electron‐probe X‐ray microanalysis of cell viability
Ions Epithelial cells Keratocytes
Na 79.5 ± 32.2 40.1 ± 19.5
Mg 16.8 ± 4.5 18.9 ± 5.3
P 216.0 ± 22.1 284.3 ± 44.1
S 53.5 ± 12.3 62.3 ± 17.4
Cl 182.0 ± 58.3 143.5 ± 32.6
K 289.7 ± 45.4 439.7 ± 73.3
Ca 9.7 ± 5.4 17.7 ± 10.7
K/Na 3.6 11.0
Note. Intracellular concentrations of the major cell ions in primary cultures
of cornea epithelial cells and keratocytes as determined by electron‐probe
X‐ray microanalysis. Values correspond to average ± standard deviation (in
mmol/kg dry weight), except for the dimensionless K/Na ratio.
RICO‐SÁNCHEZ ET AL. 2145and a good proliferation rate in culture. In contrast, cultured corneal
epithelial cells exhibit a typical cobblestone morphology (Figure 1b,c;
Miguel Alaminos et al., 2006).
Product identity is essentially founded in our previously published
studies with artificial corneas (Garzón et al., 2014; Gonzalez‐Andrades
et al., 2009). Briefly, these studies showed that the TEAHC had the
appearance of a thin translucentmembrane (Figure 1d), structurally ana-
logue to native corneal tissue (Figure 1e). Corneal epithelial cells had the
ability to form a normal stratified layer of differentiated cells with well‐
developed intercellular junctions (desmosomes, tight, and gap junctions)
due to air‐contact stimuli. These data were consistent with an appropri-
ate process of cell and tissue differentiation as determined by immuno-
histochemistry and mRNA microarrays (Gonzalez‐Andrades et al.,
2009). Regarding the latter, total RNA corresponding to bioengineered
corneas and primary cultures of epithelial cells and keratocytes (2 sam-
ples of each type) was extracted using the Qiagen RNeasy System
(Qiagen, Mississauga, Ontario, Canada), following the manufacturer's
recommendations, and comprehensive genome‐wide gene expression
analysis was carried out to quantify the global gene expression in each
sample. Results of the genome‐wide analysis are publically available at
the public repository Gene Expression Omnibus ref. GSE86584.
TEAHC samples were compared against both epithelial cells and
keratocytes. Overall, considering TEAHC as the baseline, 3,205 genes
were found to be differentially expressed (DEGs), 1,200 of them being
upregulated in TEAHC. DEGs were obtained applying a cut threshold
of false discovery rate <0.05 and a fold change value of ±2. Figure 5
a shows the hierarchical clustering of the 3,205 DEGs.
First, we analyzed the gene expression of a set of genes of specific
interest in corneal epithelium development. TEAHC showed similar
expression of genes JUP (PKG3, plakoglobin 3), DSG3 (desmoglein 3),
DSP (desmoplakin), TJP2 (ZO‐2, zonula occludens 2), SPRR1 (Small Pro-
line Rich Protein 1B), and GJA4 (CX37, connexin 37), as compared with
primary cultures of corneal epithelial cells, thus confirming the immu-
nohistochemistry findings and indicating the presence of efficient
adherent, tight, and gap cell–cell junctions in the artificial corneal epi-
thelium. Gene expression of other important genes involved in the
morphogenesis of an epithelium such as KLK7, KRT16, KRT18,
KRT24, or FGF7 are also shown (Figure 5b).
Concerning potency, as corneal epithelium acts as a potent ultravi-
olet (UV) light filter, we evaluated the TEAHC capacity to act as a
shield against potential oxidative injury to intraocular tissues. The
TEAHC stroma showed proper UV light‐absorption capabilities
(Ionescu et al., 2010). Moreover, the TEAHC also resembled the bio-
mechanical behavior—in terms of viscoelasticity, resistance and elastic-
ity—and optical transparency of the native cornea with a stable,
resilient, and elastic matrix (De La Cruz Cardona et al., 2011; Ionescu
et al., 2011; Scionti et al., 2014).
Additionally, it is necessary to ensure that the primary cell cultures
are viable, both after several passages (two passages for keratocytes,
epithelial cells are obtained from limbal explant methods) and at the
moment of its use. In this regard, we used electron‐probe X‐ray micro-
analysis (EPXMA) as a very sensitive method to determine cell viability
on subcultured cornea cell cultures on pioloform‐covered plated goldgrids as previously published (Garzón, Carriel, et al., 2012; M. Alaminos
et al., 2007). To determine total ion content of each cell type—epithelial
cells and keratocytes—we used the peak‐to‐local background ratio
methodwith reference to standards composed of 20% dextran contain-
ing known amounts of inorganic salts. All determinations were per-
formed on the central area of the cell nucleus. The intracellular
concentration of each ion is associated to cell viability, therefore the
K/Na ratio above 3 of both cell types indicated a high viability after
the expansion passages (Table 1). This microanalysis was only per-
formed in the primary cell culture, as the application of EPXMA in 3‐D
tissues is not possible with the current technology (M. Alaminos et al.,
2008, 2007; Garzón, Carriel et al., 2012; Rodriguez‐Morata et al., 2008).
Finally, we further analyzed cell function, viability, and tumorigenic
potential of the TEAHC by determining mRNA expression levels of a
few specific genes, following AEMPS recommendations. As shown in
Figure 2c, all samples expressed high levels of the cell proliferation
marker PCNA, especially the primary cell cultures, and low levels of
the pro‐apoptotic gene CASP9. Crystallin gene LDHA, involved in cor-
neal transparency, was highly expressed by both cell cultures and the
TEACH (Figure 2c; Miguel Alaminos et al., 2006). These results
complemented our aforementioned data regarding intercellular junc-
tions and other differentiation‐related genes. Expression levels of
TERT, MRAS, and C‐MYC genes were not different among conditions
(Figure 2c).2.3 | In vivo evaluation in a rabbit model
The rabbit eye is a gold‐standard model for ophthalmic research
because of its relatively large size and its practicality in ophthalmic
surgical procedures. Currently, the albino New Zealand rabbit is one
of the most accepted animal models for evaluating the biocompatibil-
ity of intraocular implants and lenses. In vivo analysis of the ATMP
was performed by grafting this bioengineered tissue on the eye sur-
face of New Zealand rabbits by anterior lamellar keratoplasty. Initial
in vivo results presented for the scientific advice request to the
AEMPS were completed and further confirmed with data from new
FIGURE 2 Microarray profiling of mRNA expression in primary cell cultures and tissue‐engineered anterior human cornea (TEAHC). (a)
Hierarchical clustering of the 3,205 differentially expressed genes (condition FDR F‐test <0.05 and fold change ±2) in TEAHC compared with
epithelial cells and keratocytes. (b) Selected genes related to corneal epithelium development and morphogenesis. (c) Selected genes related to
corneal transparency (LDHA), proliferation (PCNA), apoptosis (CASP9), and malignant transformation (TERT, C‐MYC, andMRAS) [Colour figure can be
viewed at wileyonlinelibrary.com]
2146 RICO‐SÁNCHEZ ET AL.in vivo studies carried out to increase the number of New Zealand rab-
bits to a total of 17. In each animal, the left eye was operated and the
right eye was left as control. First, animals were deeply anesthetized
by intramuscular injection of xylazine (5 mg/kg) and ketamine (25
mg/kg), and proparacaine drops were then instilled as local anesthesia
during and after the surgical procedure. Then, one third of the total
thickness of the central cornea was microsurgically removed from
the left cornea. To do so, a partial thickness trephination was per-
formed with a keratotome, followed by intrastromal manual dissection
with a sharp crescent and a blunt spatula. After the native anterior
cornea was removed, the TEAHC‐bioengineered cornea was trimmed
to the diameter of the corneal defect with a trephine and surgically
implanted at the defect site using 10/0 nylon stitches. The animals
were followed for up to 12 months after implantation, and the follow-
ing clinical parameters were evaluated: presence of edema, neovascu-
larization, infection, inflammation, and tumorigenesis. For evaluation,
the animals were examined using a slit lamp and by optical coherence
tomography (OCT). This research was approved by the institutional
experimentation committee (approval numbers 01‐09‐15‐313 and
25‐06‐2018‐099), and all animals were treated according to the
national and international rules of animal welfare, including the
ARVO Statement for the Use of Animals in Ophthalmic and Vision
Research.
TheTEAHC proved to be manageable and suturable to the recipient
bed, showing adequate strength and elasticity for surgical manipulation
(Carriel, Garzón, Alaminos, &Campos, 2011). As preliminary evidence of
efficacy, we observed recovery of corneal integrity and a progressiveimprovement of transparency levels, especially after 6 months of treat-
ment (Figure 3a–d). In addition, OCT evaluation of the grafted TEAHC
showed a proper structural integrity of the whole cornea, although an
interface between the native cornea and the TEAHC graft was still
detectable after 6 months of the procedure. Corneal tissue above and
below this interface was similar in the OCT analysis (Figure 3e,f).
Histological analysis of theTEAHC showed that the graft was prop-
erly integrated in the animal cornea 6 months after implantation, and
cells kept their adequate corneal differentiation status. More precisely,
the corneal epithelium showed optimum stratification and cohesive-
ness, whereas the corneal stroma exhibited adequate structural con-
formation based on collagen lamellae. Although stroma was very
similar to native control, our analysis showed that most apical stromal
lamellae—corresponding to the grafted areas—were slightly more irreg-
ular and heterogeneous than the most basal layers, which were very
similar to control samples (Figure 3g,h).
Regarding in vivo biodistribution, the histological analysis of biop-
sies of grafted animals showed no local migration to surrounding tis-
sues, nor any sign of systemic cell distribution. Given that the cornea
is an avascular tissue, and the topical route of administration of the
product, no further safety results were requested by the competent
authority. Finally, the favorable toxicological profile of the TEAHC
was confirmed, as all animals survived with no toxic effects derived
from the corneal implant. Regarding local tolerance, an initial inflam-
matory process was detected at the anterior surface of the eye, which
tended to disappear 3 to 6 months after the surgical procedure
(Figure 3b–d). Yet, no local infection, granuloma, tumorigenesis, or
FIGURE 3 In vivo and histological
evaluation of tissue‐engineered anterior
human cornea (TEAHC) grafted on the eye
surface of laboratory rabbits. (a) Control
nonoperated cornea, (b) grafted TEAHC after
3 weeks, (c) grafted TEAHC at 3 months, (d)
grafted TEAHC after 6 months, (e) optical
coherence tomography (OCT) analysis of the
control nonoperated cornea, and (f) OCT
analysis of the grafted TEAHC after 6 months.
The white arrow shows a heterogeneity area
at the central stroma. (g) Histological study of
native control and (h) TEAHC grafted in vivo
in laboratory rabbits for 6 months using
hematoxylin and eosin staining [Colour figure
can be viewed at wileyonlinelibrary.com]
RICO‐SÁNCHEZ ET AL. 2147systemic side effects were detected during the follow‐up period. As
described above, the TEAHC showed complete absence of tumors or
predisposition to it, neither in the macroscopic analysis, the histologi-
cal study, nor the RNA expression levels assays.
2.4 | Production under GMP conditions
Current regulation related to the development of a clinical trial in
advanced therapies establishes that the medicinal product to be tested
must be manufactured as a clinical‐grade product in GMP facilities fol-
lowing all the regulations applicable to medicinal products and ATMPs.
Therefore, the whole manufacturing process must be transferred from
the basic research laboratory to the pharmaceutical facility, and the
regulatory agency must approve both the GMP facility and the phar-
maceutical grade production process. Production of theTEAHC is per-
formed in the Unidad de Producción Celular e Ingeniería Tisular of
Hospital Universitario Virgen de las Nieves, which belongs to the net-
work of the Andalusian Initiative for Advanced Therapies (AIAT). This
production is based on methods previously developed and reported
in the basic research laboratory, including some modifications and
additional studies in order to meet the regulatory requirements regard-
ing clinical grade in ATMP manufacturing as described (Miguel
Alaminos et al., 2006; De La Cruz Cardona et al., 2011; Garzón et al.,
2014; Gonzalez‐Andrades et al., 2009; Ionescu et al., 2011; Scionti
et al., 2014). Briefly, all materials and reagents used in the manufactur-
ing process are certified for clinical‐grade production, except for the
agarose that needs a previous conditioning phase. Also, standard in‐
process controls, as well as final product quality tests, were imple-
mented on the product according to the European Pharmacopeia as
described hereunder (Figure 4). The sterility was demonstrated bymicrobiological control of cellular products using an automated blood
culture system (Ph. Eur. 2.6.27) as well as gram and calcofluor staining.
The Mycoplasma test was performed by conventional PCR in the cul-
ture supernatant (Ph. Eur. 2.6.7). Genetic fingerprint tests was based
on PCR application of microsatellite and subsequent nucleotide
sequencing (Ph. Eur. 2.6.21). The absence of adventitious virus was
demonstrated by conventional culture in three cell lines (MRC‐5, Vero
and RD) and subsequent observation of cytopathic effect. The
absence of endotoxins was demonstrated by chromogenic endpoint
method (Ph. Eur. 2.6.14). Finally, we demonstrated that the chromo-
some number and structure was normal by G‐bands karyotype
analysis.
Keratocytes and corneal epithelial cells are kept in liquid nitrogen
until obtaining quality control results. If the results are compliant, the
cell lines will become available for manufacturing. Approximately 4
weeks before implant, the cell lines are thawed and the scaffold is
manufactured. On the day of implantation, TEAHC is nanostructured
and packaged in sterile containers immersed in culture medium.
Likewise, the translation of the basic research protocol into the
GMP environment involved the implementation of a risk management
plan in order to ensure the quality of the manufacturing process and
ultimately the safety of the patient (International Conference Harmo-
nization [ICH] Expert Working Group, 2005), a solid documentation
system at different levels (involving Standard Operating Procedures,
Master Batch Records, Working Instructions, Protocols, etc), meticu-
lous testing of all starting materials (including human tissue samples),
rigorous training of staff, and so forth. Cells and biomaterials applied
in the TEAHC have a short half‐life in vitro, which influenced the
choice of the packaging as well as transport methods. Taking this into
account, and after carrying out a stability study, we concluded that the
FIGURE 4 Clinical‐grade Production and quality controls in the production of the tissue‐engineered anterior human cornea (TEAHC) in
compliance with good manufacturing practice. (a) Quality controls and acceptance criteria defined to release each product of the manufacturing
process. H, high; HAC, human allogeneic cornea (TEAHC); K, keratocytes; LSC, limbal stem cells; M, medium. (b) Limbal cell karyotype included in
the quality controls of theTEAHC; (c) Example of the absence of microorganism in mycoplasma assay quality control [Colour figure can be viewed
at wileyonlinelibrary.com]
2148 RICO‐SÁNCHEZ ET AL.TEAHC was stable for up to 6 hr after being packed in a solid sterile
refrigerated container.2.5 | Scientific advice request to the AEMPS
With the purpose of speeding up the clinical development of ATMPs,
the AIAT provides specialized preclinical support and assessment from
a regulatory point of view. Seeking to initiate a first in human clinical
trial, a scientific advice request was carried out to the AEMPS in a
face‐to‐face meeting. All available in vitro and in vivo preclinical data
was presented and discussed, together with the ATMP manufacturing
procedure and clinical trial design, previously also submitted in an elec-
tronic dossier. An updated scientific dossier was electronically submit-
ted after incorporating new preclinical data following AEMPS requests
in the aforementioned meeting.3 | RESULTS AND DISCUSSION
This article provides a complete description of the in vitro and in vivo
studies, including the adaptation of the manufacturing process toGMP, for the development and translation of a tissue‐engineered
product to the clinic, allowing its authorization in an early, first‐in‐
human clinical trial. We believe that this successful clinical translation
experience of a tissue‐engineered product could serve as guidance
for other researchers developing this type of ATMP.3.1 | Challenges in ATMP clinical translation
One of the first steps of the translation process is to identify and clas-
sify the future medicinal product. The TEAHC belongs to the category
of tissue‐engineered ATMPs as defined by Regulation (EC) 1394/2007
and Commission Directive 2009/120/EC (“Commission Directive
2009/120/EC of 14 September 2009 amending Directive 2001/83/
EC of the European Parliament and of the Council on the Community
code relating to medicinal products for human use as regards
advanced therapy medicinal products,” 2009; “REGULATION (EC) No
1394/2007 OF THE EUROPEAN PARLIAMENT AND OF THE
COUNCIL of 13 November 2007 on advanced therapy medicinal
products and amending Directive 2001/83/EC and Regulation (EC)
No 726/2004,” 2007), which are defined as medicinal products for
RICO‐SÁNCHEZ ET AL. 2149human use containing substantially manipulated cells or tissues and
intended to regenerate, repair, or replace human tissue to achieve a
desired physiological function. As such, specific guidelines should be
followed as much for nonclinical studies as for manufacturing, quality
controls, and clinical development. This regulatory context can be chal-
lenging, as it is a well‐known fact that medicinal product standards
may not always be compatible with the typical framework of cell‐
based products, as some of them are of autologous origin, produced
in very small batch sizes, or produced using materials with high vari-
ability (in some cases impossible to standardize). Additionally, the bur-
den generated by meeting the standards of GMP in production stands
as an added complication in this particular context, as most of the
research and development of ATMPs is performed mainly by acade-
mia, hospitals, and SMEs (as is the case here; Pirnay et al., 2013).
The translation of an ATMP from basic research into a clinical‐
grade product applicable in a human clinical trial is therefore a com-
plex, integrated activity that requires professional and multidisciplinary
expertise. Clinical translation is indeed a challenging goal that a
research group cannot handle alone. At this point, involvement of stra-
tegic stakeholders is crucial, including but not limited to regulatory
experts, technology transfer offices, clinicians, manufacturing facilities,
regulatory agencies, and patient organizations. The AIAT is a publicly
funded institution that facilitated communication among all theFIGURE 5 Product development and clinical translation process of the tis
advanced therapy medicinal product from basic research into a clinical‐gra
activity that requires multidisciplinary expertise involving basic researchers
regulatory agencies, and patient organizations. The whole clinical translatio
Advanced Therapies that promotes communication among strategic stakeh
the development of the TEAHC [Colour figure can be viewed at wileyonlinstakeholders, coordinating the activities of a multidisciplinary team
and providing the regulatory expertise required for development of
the TEAHC. Early collaboration with researchers performing high‐qual-
ity basic research, clinicians to identify unmet needs, and the people
involved in the manufacturing process is key in the whole translational
process (Figure 5). A nonprofit academia entity like the AIAT repre-
sented in this particular case an opportunity to speed up the develop-
ment process of this particular ATMP facilitating the patient access to
this technology. (Cuende, 2013)3.2 | Experimental design of the TEAHC
One of the main objectives of nonclinical studies is to define the phar-
macological and toxicological effects of the experimental product. The
goals of these studies include providing information for a safe and effi-
cacious product dosage in future clinical trials (Celis et al., 2015). In
this regard, the present manuscript describes all the experimental
studies carried out for the efficient clinical translation of a
bioengineered cornea, including exhaustive preclinical studies.
To help guiding the initial development and characterization of the
product, some important issues should dictate the experimental
design: the intended clinical application; the physical, chemical,sue‐engineered anterior human cornea (TEAHC). The translation of an
de product applicable in a human clinical trial is a complex, integrated
, clinicians, manufacturing facilities, technology transfer offices,
nal process is facilitated by entities like the Andalusian Initiative for
olders and coordinates the activities of the research teams involved in
elibrary.com]
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product (form, function, fixation and formation), and its biocompatibil-
ity and interactions with cells and tissues (Lu et al., 2015). Thus, in this
report, we have showed a successful step‐by‐step process to translate
in vitro and in vivo data of a potential new therapy consisting of a
bioengineered corneal substitute for application as a topical engraft-
ment in patients with severe corneal damage. For product identifica-
tion, we used the microscopic assessment of both cells morphology,
complemented with the results of immunohistochemistry. Comple-
mentarily, we used relevant data published by the basic research group
including light, transmission, and scanning electron microscopy and
histological images of TEAHC, with and without in vitro differentiation
induction. These results were used as a proof of identity, purity, and
potency characteristics of the final product: adequate structural, bio-
mechanical behavior (viscoelasticity, resistance, elasticity), optical
properties (transparency, UV light absorption, scattering, absorbance),
epithelial stratification, differentiation, and intercellular junctions for-
mation (De La Cruz Cardona et al., 2011; Garzón et al., 2014;
Gonzalez‐Andrades et al., 2009; Ionescu et al., 2011, 2010; Scionti
et al., 2014). These findings were confirmed by comprehensive gene
expression analyses showing that the ATMP expresses numerous
genes whose functions were related to normal corneal function and
development, especially those related to epithelial cell‐cell junctions,
basement membrane, organelles synthesis, and other epithelial func-
tions. Most importantly, we used these highly sensitive microarray
analyses to demonstrate that the gene functions that were associated
to the novel ATMP were typical of cornea differentiation and develop-
ment and were devoid of malignant transformation gene functions.
Additionally, EPXMA demonstrated that both cells types included in
the final ATMP were highly viable at the moment of use in the
bioengineered cornea, with K/Na ratios above 3, which are typical of
viable human cells kept in culture, and other types of cornea cells such
as the rabbit cornea endothelial cells (M. Alaminos et al., 2007;
Garzón, Carriel et al., 2012; Garzón et al., 2012; M. Martin‐Piedra
et al., 2013). These findings were confirmed by the normal intracellular
concentrations of the rest of elements analyzed in cultured
keratocytes and epithelial cells, especially the high concentrations of
chlorine (M. Alaminos et al., 2007; Garzón, Carriel et al., 2012; Garzón,
Pérez‐Köhler, et al., 2012). Previous reports demonstrated that this
highly sensitive technology is much more accurate than standard
methods such as trypan blue and can be used for a precise analysis
of cell viability in numerous cell types (M. A. Martin‐Piedra et al.,
2014; Vico et al., 2015).
One of the most important issues that must be addressed before
the first use in humans is the safety of the administration of therapeu-
tic product. On the one hand, it has been observed that occurrence of
cell abnormalities appears to be mainly related to the manufacturing
process as opposed to patient‐specific factors; it is therefore impor-
tant to determine whether the manufacturing process leads to chro-
mosomal abnormalities during preclinical development (Barkholt et
al., 2013). Consequently, all ATMP need to be analyzed by karyotyping
to demonstrate the total absence of chromosomal abnormalities
before clinical use. This should be taken into account to determinethe required number of cells of each type, because karyotyping usually
requires a high number of cells. Additionally, in vivo studies carried out
on our TEAHC corneal substitute revealed that it was not associated
to the development of any local infection, granuloma, or systemic side
effects during the follow‐up period. No alterations that could lead to a
malignant or tumorigenic transformation of the product cells were
found.
Overall, the in vitro characterization results presented in this article
are consistent with an adequate primary pharmacology of the medici-
nal product, and these findings were confirmed in vivo by a full inte-
gration and biocompatibility of the TEAHC corneal substitute in
rabbits.3.3 | Adapting the ATMPS development process
Every small step of the preclinical research and product development
plan needs to be established and adaptions have to be applied at dif-
ferent levels in the ATMP research process. Major gaps in ATMP
development should be overcome by strategic rational customization
of the experimental design. Regarding dosage selection for example,
it is important to note that the intended objective is to evaluate a
three‐dimensional artificial tissue, not a cell suspension. For this rea-
son, the number of cells to be implanted with theTEAHC corresponds
to the number required for the generation of a human corneal substi-
tute, in terms of functional confluence of cells allowing differentiation
as a stratified epithelium, with approximately 500,000 cells per layer
per construct (Miguel Alaminos et al., 2006). Additionally, it is neces-
sary to consider that theTEAHC could vary in size as it should be large
enough to cover the lesion, therefore the total number of cells to be
implanted will depend on the size of the corneal defect (or keratec-
tomy) in each patient. Another main issue that required adaptive refor-
mulation of the experimental strategy is biodistribution. In general,
conventional pharmacokinetic studies (commonly used for chemical
drugs) are not applicable to this type of products. According to the
Guideline on human cell‐based medicinal products, “conventional
ADME (Absorption, distribution, metabolism & excretion) studies are
usually not relevant for this type of products. However, studies should
be carried out to demonstrate tissue distribution, viability, trafficking,
growth, phenotype and any alteration of phenotype due to factors in
the new environment” (Committee for Medicinal Product for Human
Use [CHMP], 2008). In fact, biodistribution was one of the main con-
cerns raised by AEMPS during the scientific advice meeting. In our
case, the in vivo assays were used to evaluate biodistribution, mea-
sured as migration and persistence in the relevant animal model
(EMEA/CHMP/410869/2006). However, given that cornea is an avas-
cular tissue, the animal model used, and the route of administration
through topical engraftment, it was agreed that physical evaluation
of the eye surface, further confirmed by histological study and OCT,
confirming no migration to surrounding tissues or signs of systemic cell
distribution would be sufficient in this specific product. The fact that
the TEAHC was implanted on the central cornea has two important
advantages as compared with other medicinal products. First, this
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grafted tissue because of its accessibility for exploration and sampling.
Second, the fact that the cornea is naturally free from vascularization
hinders the possibility of cell distance migration through the blood-
stream. Probably, other types of ATMPs will require much stricter con-
trols to guarantee biosafety and proper biodistribution. Regarding the
toxicity profile and local tolerance, clinical trial design was founded in
the safety issues identified in the animal model using the same route
(local implant on the corneal surface by anterior lamellar keratoplasty)
and frequency (a graft per patient) of administration.
In parallel with preclinical product development, the manufacturing
protocol was adjusted to produce a clinical‐grade TEAHC. The basic
research production process was not essentially modified, yet raw
materials, product manipulation, facility, and staff had to meet specific
GMP‐compliant requirements as described previously. After successful
definition and validation of the entire GMP production methods, the
manufacturing process needs to be authorized by the competent
authority. The basis for this approval is the investigational medicinal
product dossier, which serves as the primary document describing
manufacturing methods and control assays of the product.
We carefully considered available options to reduce materials from
xenogeneic origin; however we believe that using a xeno‐free culture
media may not have led to an easier regulatory approval at the time.
The fetal bovine serum used had a certificate of suitability issued by
the European Directorate for the Quality of Medicines (Council of
Europe, 2018), therefore our procedure fully complied with the regula-
tory recommendations for the use of fetal bovine serum, ruling out any
possibility of bovine spongiform encephalopathy transmission and
ensuring patient safety (EMA/CAT/80183/2014; EMA/CHMP/BWP/
457920/2012 rev.1.; Regulation (EC) 999/2001 of the European
Parliament and of the Council).
However, there is nowadays an increasing pressure form regula-
tory agencies to incorporate nonxenogenic culture media in clinical‐
grade manufacturing procedures, and our group is at the moment
working on xeno‐free strategies for cell expansion.
A Phase I trial is designed to assess the safety of the investiga-
tional product and to identify any possible side effects. For a con-
ventional clinical Phase I trial with a new product, usually healthy
adult volunteers are recruited; however, due to the nature of this tis-
sue‐engineered product, this traditional set‐up is not appropriate: no
healthy volunteers could be recruited as corneal transplantation is
only indicated in preexisting severe corneal defects. For obvious rea-
sons, intentional creation of such defects would be unethical. There-
fore, the selected approach for the trial was to recruit directly the
patients that would also gain most benefit from this innovative ther-
apy. In addition, in order to take the most conservative approach,
trial selection criteria limited participation to patients with severe
corneal defects in whom other conventional therapies were ineffec-
tive (including donor keratoplasty). The methodological design of
the clinical trial should be established as early as possible, as the
intended route, dose, and frequency of administration are key
aspects to take into account in the experimental design of the pre-
clinical development of the product according to Europeanregulations (ICH Topic M3(R2), CPMP/ICH/286/95.30). Furthermore,
it is advisable to establish an independent data safety monitoring
committee that may provide an unbiased point of view in the evalu-
ation of the safety data of the study participants. Especially in early
clinical trials testing products like the TEAHC, which may potentially
cause serious impairments, this committee helps the sponsor and
principal investigators with their expertise, ensuring patient safety is
warranted anytime during the trial. Figure 5 illustrates the develop-
ment process pathway that successfully paved the way toward the
start‐up of the early clinical trial testing the product in 2014
(Figure 1f; Miguel González‐Andrades, Mata, et al., 2017). This is a
Phases I and II, randomized, controlled, open‐label clinical trial, cur-
rently ongoing in 11 Spanish hospitals (Miguel González‐Andrades,
Mata, et al., 2017), to evaluate the safety and feasibility, as well as
clinical efficacy evidence, of the TEAHC in adults with severe trophic
corneal ulcers or its sequelae. The initial phase of the trial (n = 5) was
completed, and preliminary data have already been presented (M.
González‐Andrades et al., 2017).3.4 | Scientific advice with regulators
Early dialogue with regulators is encouraged for ATMPs development
in order to speed up the progress of research, optimize the available
resources, and speed up clinical use evaluation. The European Medi-
cines Agency as well as the National Competent Authorities can give
scientific advice to medicine developers, ensuring the appropriate
tests and studies are performed and no major objections are likely to
be raised during the evaluation of human clinical trials or marketing
authorizations applications. Scientific advice is particularly useful in
ATMPs development, as the information contained in the EU guide-
lines or guidance documents may be insufficient in certain relevant
aspects, or it may be recommendable to deviate from the available
guidance in some specific cases. Scientific advice can be requested at
any stage of development of a medicine, and the guidance received
is not legally binding to any future authorization applications for the
product concerned. Accordingly, a scientific advice was requested to
the AEMPS in 2010 to provide guidance over the TEAHC preclinical
development plan. As a result, further preclinical studies as well as spe-
cific questions regarding GMP production were requested to complete
the clinical trial application dossier. Concerning measures to avoid
graft rejection, the high biocompatibility of fibrin–agarose scaffold
was proved in several in vivo models (oral mucosa, Fernández‐
Valadés‐Gámez et al., 2016; skin, Carriel et al., 2012; peripheral nerve,
Carriel et al., 2013), where no signs of rejection or inflammation were
found. TheTEAHC is manufactured with cells (epithelial/corneal fibro-
blasts) from different allogeneic donors, which may imply an increased
risk of graft rejection. However, HLA‐matching is generally not
required in donor corneal transplantation, owing to the immune privi-
lege of the cornea. Nevertheless, in our clinical trial testing theTEAHC
(Gonzalez‐Andrades et al., 2017), the potential risk of graft rejection is
addressed by per protocol administration of steroid eye drops over the
first year after receiving the implant.
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Previous researches account for influence of commercialization criteria
(e.g., IP landscape, market size, competitors, reimbursement, and adop-
tion by users) in the development of the product (e.g., preclinical test-
ing against competing products). The more valuable their studies
become in supporting a marketing application, the higher the chance
they withstand in raising necessary funding or partnering with an
existing company (Lu et al., 2015). Nowadays, there is an intense
research, development, and commercialization activity in the field of
corneal substitutes that can be easily justified by cost–benefit
improvement and higher intervention accessibility to a larger group
of people (Ghezzi, Rnjak‐Kovacina, & Kaplan, 2015). The TEAHC was
patented in an early stage of development for two main reasons: on
the one hand, having a firm grasp on the importance of intellectual
property from the outset can reduce future chances of financial loss
(Juetten, 2016), and on the other hand, the bioengineered tissue that
we have developed has shown important properties to be a future suc-
cessful ATMP. Proactive and early intellectual property protection of
the product as well as early market research are highly recommended
for the clinical translation of an ATMP. In this sense, the patent of the
TEAHC was requested in parallel to its preclinical development (PCT/
ES2010/070569).4 | CONCLUSIONS
The successful development of ATMPs for clinical application has to
overcome many obstacles such as the challenge in the interpretation
of ATMPs regulation and guidelines, the heavy workload generated
by the standards of GMP and GCP, and the financial burden of the
whole drug development process. These difficulties become almost
unbridgeable when undertaken by academia or SMEs. At this point,
clinical translation of ATMPs can be facilitated by research platforms
like the AIAT promoting the collaboration among strategic stake-
holders, as well acting as a counseling entity for the implementation
of specific regulations and guidelines. Furthermore, a strategy should
be set‐up for the experimental development of the product, allowing
the necessary adjustments according to a rational application of the
guidelines at the specific target intended for its clinical use. Despite
the long list of constraints, the experience reported in this article
proves that, with strategic planning and support, clinical translation
in the academic context can ultimately excel providing patients the
access to this innovative type of medicines.ACKNOWLEDGEMENTS
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